News

Read our latest news, and find more about us and our portfolio companies.

2020/11/12
Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC

Xilio Therapeutics today announced the presentation of preclinical data of its lead investigational therapies at the 35th Annual Meeting of The Society for Immunotherapy of Cancer (SICT 2020).

2020/10/28
Galecto Announces Pricing of Initial Public Offering

Galecto, Inc. today announced the pricing of its initial public offering of 5,666,667 shares of common stock at a public offering price of $15.00 per share.

2020/10/22
STORM Therapeutics selects first-in-class clinical candidate targeting METTL3

STORM Therapeutics today announces that STC-15, its first-in-class drug candidate targeting METTL3, has been selected for development towards first in human clinical studies

2020/09/30
Synthetic Biology start up NanoSyrinx secures capital to develop its fully customisable platform for intra-cellular engineering

NanoSyrinx is the first company to engineer ‘nanosyringes’, a selective non-viral peptide and protein delivery system identified in an undisclosed organism. The company will focus on direct cytosolic delivery of genome editing enzymes and therapeutic proteins in vivo, with key applications in the cell and gene therapy space.

2020/09/25
Mosa Meat raises Series B funding to prepare for large-scale cultured meat production

Mosa Meat announced the first closing of $55M as part of a larger Series B funding round

2020/09/25
Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials

2020/09/08
Rapid prototyping and validation of SARS-CoV-2 clinical diagnostic workflows

From design to prototyping, validation, and frontline diagnostic testing in nine weeks

2020/08/25
Sonde Health purchases NeuroLex Labs’ voice platform and 500K biometric samples

Sonde Health acquires NeuroLex Laboratories, Inc. to forms one of the world’s preeminent biobanks focused on vocal biomarkers

2020/07/29
DNA Script Expands Series B to $89M

Casdin Capital leads the $50M extension; funding will support commercial launch of SYNTAX™️ — the world’s first enzymatic DNA printer.

2020/07/23
Xilio Therapeutics Appoints Paul J. Clancy to its Board of Directors

Mr. Clancy brings significant strategic, financial and operational leadership experience in the biotechnology and pharmaceutical industry

2020/07/23
Synaffix Announces Third Deal Expansion by ADC Therapeutics

Synaffix B.V. announces that ADC Therapeutics SA has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies

2020/07/08
Sonde Health Launches New Voice-Enabled Health Screening Tool to Help Employers Return to Work During the Global Pandemic

Sonde One combines 6-second voice analysis, COVID-19 questionnaire, and body temperature reading in one app

2020/06/18
Micropsi Industries Secures Two New Specialized Investors

Our Existing Backers Will Also Supply Fresh Investment

2020/06/15
Akili Announces FDA Clearance of EndeavorRx™ for Children with ADHD, the First Prescription Treatment Delivered Through a Video Game

Shown to improve attention function, EndeavorRx is backed by data from five clinical studies, including a prospective, randomized controlled trial

2020/05/20
Computers modelled on the human brain

Comment from Kai Beckmann, member, executive board, Merck KGaA

2020/05/19
Galecto Appoints New Chair and Strengthens Board of Directors

Appoints Amit Munshi as Chair, deeply experienced industry executive, CEO of Arena Pharmaceuticals

2020/04/27
Xilio Therapeutics Appoints Martin H. Huber, M.D as Chief Medical Officer

To Lead XTX201 (Tumor-Selective IL-2) and XTX101 (Tumor-Selective aCTLA-4) into the Clinic while Xilio Continues to Advance its Tumor-Selective Cytokine Pipeline

2020/04/22
Akili Announces ENDEAVORTM Digital Attention Treatment is Now Available for Children with Attention Deficit Hyperactivity Disorder (ADHD) under FDA’s COVID-19 Enforcement Discretion Guidance

ENDEAVORTM (AKL-T01) is now available for use by children with attention deficit hyperactivity disorder (ADHD) and their families

2020/04/22
FoRx Therapeutics AG Raises EUR 10 Million Seed Round

First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer Seasoned Biotech Executive Colin Goddard Joins as Executive Chairman

2020/04/09
Seeqc Gains Over $11 Million in Funding to Introduce Fully Digital Quantum Computing

Spinout Announces Investment From M Ventures, the Strategic, Corporate Venture Capital Arm of Merck KGaA, Darmstadt, Germany, to Deliver Scalable, Energy-Efficient Quantum Computing Systems

2020/02/25
Scipio bioscience raises €6.0 M Series A financing

To develop and launch a kit dedicated to sample preparation for single-cell RNAsequencing

2020/02/10
Artios Pharma Strengthens Clinical Development Team with Senior Appointments

Artios Pharma Limited today announces the appointment of Bryony Harrop as Vice President (VP) of Clinical Development

2020/02/04
iOnctura Expands its Clinical Advisory Board

iOnctura SA announces the addition of new members to its Clinical Advisory Board (CAB)

2019/07/19
First programmable memristor computer aims to bring AI processing down from the cloud

Circuit elements that store information in their electrical resistances enable a brain-like form of computing, storing and processing information in the same place